QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September
30, 2017

OR

¨

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from____ to ____

Commission File Number: 001-32295

FENNEC PHARMACEUTICALS
INC.

(Exact Name of Registrant as Specified in
Its Charter)

British Columbia, Canada

(State or Other Jurisdiction of

Incorporation or Organization

20-0442384

(I.R.S. Employer

Identification No.)

PO Box 13628, 68 TW Alexander Drive

Research Triangle Park, North Carolina

(Address of Principal Executive Offices)

27709

(Zip Code)

Registrant's Telephone Number, Including
Area Code: (919) 636-4530

Indicate by check mark whether the registrant: (1) has filed all
reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. YES x NO ¨

Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files).

Yes þ No¨

Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated
filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

¨

Accelerated Filer

¨

Non-Accelerated Filer

¨

(Do not check if smaller reporting company)

Smaller reporting company

x

Emerging growth company

¨

If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicated by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨ NO x

As November 13, 2017, there were 15,869,978 shares of Fennec Pharmaceuticals
Inc. common stock outstanding.

Fennec Pharmaceuticals Inc. (“Fennec”)
is a British Columbia corporation. Fennec, together with its wholly owned subsidiaries Oxiquant, Inc. (“Oxiquant”)
and Fennec Pharmaceuticals, Inc., both Delaware corporations, and Cadherin Biomedical Inc. (“CBI”), a Canadian corporation,
collectively referred to herein as the “Company,” is a biopharmaceutical company focused on the development of PEDMARKTM
(a unique formulation of Sodium Thiosulfate (“STS”)) for the prevention of ototoxicity from cisplatin in pediatric
patients. With the exception of Fennec Pharmaceuticals, Inc., all subsidiaries are inactive.

These unaudited interim condensed consolidated
financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America
(“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for
the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.

During the nine months ended September 30,
2017, the Company incurred a loss from operations of $4,436. At September 30, 2017, it had an accumulated deficit of $119,078 and
had experienced negative cash flows from operating activities during the nine months ended September 30, 2017 in the amount of
$2,321.

These circumstances raise substantial doubt
as to the ability of the Company to meet its obligations as they come due and, accordingly, the use of accounting principles applicable
to a going concern may not be appropriate. The Company will need to obtain additional funding in the future in order to finance
the Company’s business strategy, operations and growth through the issuance of equity, debt or business combinations. If
the Company fails to arrange for sufficient capital on a timely basis, the Company may be required to curtail its business activities
until it can obtain adequate financing. However, as of September 30, 2017, we had cash and cash equivalents of $9,688 and believe
that our cash resources will be sufficient to meet our cash requirements through and beyond current fiscal year.

These financial statements do not reflect the
potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet
classifications used, that would be necessary if the going concern assumption were not appropriate.

2.

Significant Accounting Policies

Basis of presentation

The accompanying unaudited interim condensed
consolidated financial statements have been prepared in accordance with US GAAP and are the responsibility of the Company’s
management. These unaudited interim condensed consolidated financial statements do not include all of the information and notes
required by US GAAP for annual financial statements. Accordingly, these unaudited interim condensed consolidated financial statements
should be read in conjunction with the Company's audited consolidated financial statements and notes filed with the Securities
and Exchange Commission (“SEC”) in the Company's Annual Report on Form 10-K for the year ended December 31, 2016. The
Company's accounting policies are consistent with those presented in the audited consolidated financial statements included in
the Annual Report on Form 10-K for the year ended December 31, 2016. These unaudited interim condensed consolidated financial statements
have been prepared in U.S. dollars. All amounts presented are in thousands except for per share amounts.

Use of estimates

The preparation of financial statements in
conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities as of the date of the interim condensed consolidated financial statements and
the reported amounts of expense during the reporting period. Actual results could differ from those estimates.

In the opinion of management, these unaudited
interim condensed consolidated financial statements include all adjustments, which are normal and recurring in nature, necessary
for the fair presentation of the Company’s financial position at September 30, 2017 and to state fairly the results for the
periods presented. The most significant estimates utilized during the quarter ended September 30, 2017 included estimates necessary
to value derivative instruments, disclosed in Note 4.

New accounting pronouncements

In February 2017, the FASB issued ASU No. 2017-05,
“Other Income - Gains and Losses from the Derecognition of Nonfinancial Assets (Subtopic 610-20): Clarifying the Scope of
Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets” (“ASU 2017-05”). ASU 2017-05
is meant to clarify the scope of the original guidance within Subtopic 610-20 that was issued in connection with ASU 2014-09, as
defined below, which provides guidance for recognizing gains and losses from the transfer of nonfinancial assets in contracts with
noncustomers. ASU 2017-05 also added guidance for partial sales of nonfinancial assets. ASU 2017-05 is effective for our fiscal
year beginning December 31, 2018 and we are required to adopt ASU 2017-05 concurrent with the adoption of ASU 2014-09. We are currently
evaluating the impact that the adoption of ASU 2017-05 may have on our consolidated financial statements and disclosures.

In May 2017, the Financial Accounting Standards
Board (“FASB”) issued Accounting Standards Update 2017-09, Compensation—Stock Compensation (Topic 718): Scope
of Modification Accounting (“ASU 2017-09”). The FASB issued ASU 2017-09 to clarify and reduce both (i) diversity
in practice and (ii) cost and complexity when applying the guidance in Topic 718, to a change to the terms and conditions of a
share-based payment award. This guidance is effective for the Company as of the fourth quarter of its fiscal year ending December
31, 2018. Early adoption is permitted. The amendments in this ASU should be applied prospectively to an award modified on or after
the adoption date. The Company is currently evaluating the impact of this updated standard, but does not believe this update will
have a significant impact on its consolidated financial statements.

In May 2014, the FASB issued ASU 2014-9, Revenue
from Contracts with Customers (Topic 606), to clarify the principles for recognizing revenue. This update provides a comprehensive
new revenue recognition model that requires revenue to be recognized in a manner to depict the transfer of goods or services to
a customer at an amount that reflects the consideration expected to be received in exchange for those goods or services. In August
2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date, which
delayed the effective date of the new standard from January 1, 2017 to January 1, 2018. The FASB also agreed to allow entities
to choose to adopt the standard as of the original effective date. In March 2016, the FASB issued ASU No. 2016-08, Revenue from
Contracts with Customers (Topic 606): Principal versus Agent Considerations, which clarifies the implementation guidance on principal
versus agent considerations. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers (Topic 606):
Identifying Performance Obligations and Licensing, which clarifies certain aspects of identifying performance obligations and licensing
implementation guidance. In May 2016, the FASB issued ASU No. 2016-12, Revenue from Contracts with Customers (Topic 606): Narrow-Scope
Improvements and Practical Expedients related to disclosures of remaining performance obligations, as well as other amendments
to guidance on collectability, non-cash consideration and the presentation of sales and other similar taxes collected from customers.
These standards have the same effective date and transition date of January 1, 2018. The new revenue standard allows for either
full retrospective or modified retrospective application. The Company currently does not have any revenue and therefore does not
expect this update will have a significant impact on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02,
Leases, which amends the accounting guidance related to leases. These changes, which are designed to increase transparency
and comparability among organizations for both lessees and lessors, include, among other things, requiring recognition of lease
assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Adoption and implementation
of the guidance is not required by the Company until the beginning of fiscal 2019, although early adoption is permitted. The Company
has not yet completed its assessment of the impact that adoption of this guidance will have on its financial statements.

In March 2016, the FASB issued ASU 2016-09,
Improvements to Employee Share-Based Payment Accounting, which amends the accounting for share-based payment transactions.
These changes, which are designed for simplification, involve several aspects of the accounting for share-based transactions, including
the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash
flows. The Company adopted this ASU as of January 1, 2017. There has been no impact to the financial statements

Cash and cash equivalents

Cash equivalents consist of highly liquid investments
with original maturities at the date of purchase of three months or less. The Company places its cash and cash equivalents in investments
held by highly rated financial institutions in accordance with its investment policy designed to protect the principal investment. At
September 30, 2017, the Company had $9,688 in cash and money market accounts ($3,926 at December 31, 2016). At September 30, 2017,
the Company held $440 in cash of which $282 (as presented in US dollars) was in Canadian dollars ($51 at December 31, 2016 as presented
in US dollars). At September 30, 2017, the Company held $9,248 in money market investments. Money market investments typically
have minimal risks. The Company has not experienced any loss or write-down of its money market investments since inception.

3.

Earnings per Share

Earnings per common share is presented under
two formats: basic earnings per common share and diluted earnings per common share. Basic earnings per common share is computed
by dividing net income attributable to common shareholders by the weighted average number of common shares outstanding during the
period. Diluted earnings per common share is computed by dividing net income by the weighted average number of common shares outstanding
during the period, plus the potentially dilutive impact of common stock equivalents (i.e. stock options and warrants). Dilutive
common share equivalents consist of the incremental common shares issuable upon exercise of stock options and warrants. The following
table sets forth the computation of basic and diluted net loss per share:

The following outstanding options and warrants
were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would
have had an anti-dilutive effect:

Three Months Ended
September 30,

Nine Months Ended
September 30,

2017

2016

2017

2016

Options to purchase common stock

2,361

2,422

2,361

2,422

Warrants to purchase common stock

1,362

1,749

1,362

1,749

4.

Derivative Instruments

The Company's outstanding
warrants denominated in Canadian dollars are not considered to be indexed to its own stock because the exercise price is denominated
in Canadian dollars and the Company's functional currency is United States dollars. Therefore, these warrants have been treated
as derivative financial instruments and recorded at their fair value as a liability. All other outstanding convertible instruments
are considered to be indexed to the Company's stock, because their exercise price is denominated in the same currency as the Company's
functional currency, and are included in stockholders' equity.

The Company's derivative
instruments include options to purchase 39 common shares, the exercise prices for which are denominated in a currency other than
the Company's functional currency, as follows:

·

Contractor options to purchase 20 common shares exercisable at CAD$1.89 per whole common share
that expire on November 19, 2017;

·

Contractor options to purchase 17 common shares exercisable at CAD$1.62 per whole common share
that expire on April 4, 2018;

·

Contractor options to purchase 2 common shares exercisable at CAD$2.43 per whole common share that
expire on May 18, 2018.

These options have been recorded at their fair
value as a liability at issuance and will continue to be re-measured at fair value as a liability at each subsequent balance sheet
date until they are exercised, forfeited or expire. Any change in value between reporting periods will be recorded as unrealized
gain/(loss). The fair value of these warrants and options is estimated using the Black-Scholes option-pricing model using the following
assumptions for the current balance sheet date: expected dividend 0%; risk-free interest rate 0.76%; expected volatility between
97% - 100%; and an expected life between 0.5 – 0.63 years.

Comparative data related to gain/(loss) recorded
on re-measurement of the derivative liability for the three and nine month period ended September 30, 2017 and 2016 are summarized
in the table below. There is no cash flow impact for these derivatives until the warrants and/or options are exercised. If these
warrants or options are exercised, the Company will receive the proceeds from the exercise at the current exchange rate at the
time of exercise.

During the fiscal
years ended December 31, 2011 and 2010, the Company issued 36 and 29, respectively, options to contractors with a Canadian dollar
denominated strike price. Consequently, the Company now has derivatives relating to these options since the strike price is denominated
in a currency other than the US dollar functional currency of the Company. While there is an exception to this rule for employees
in ASU 2010-13 "Compensation-Stock Compensation (Topic 718): Effect of denominating the exercise price of a share based payment
award in the currency of the market in which the underlying equity security trades", no such exception exists for contractors.
These options will be marked to market until the earlier of their expiry, exercise or forfeiture.

Canadian dollar denominated options issued
to contractors vest immediately and are treated as derivative liabilities. In the case a derivative option is exercised, upon the
exercise date, the Company extinguishes the derivative liability, records the cash received and the shares issued into common stock
and additional paid in capital accordingly. During the three and nine month period ended September 30, 2017, there was an exercise
of 1 Canadian denominated option being treated as a derivative liability. This exercise resulted in $2 gross proceeds to the Company.

5.

NASDAQ Listing

On September 13, 2017, the Company began trading
its common shares on the Nasdaq Capital Market (“Nasdaq”) under the ticker symbol “FENC”. Prior to the
Nasdaq listing, the Company had been trading on the OTCB Marketplace (the “OTCQB”) since January of 2009 under the
ticker symbol “FENCF”.

6.

Stockholders' Equity

Authorized capital stock

The Company’s authorized capital stock
consists of an unlimited number of shares of no par common stock.

Warrants to Purchase
Common Stock

The Company has warrants outstanding to purchase
common stock priced in U.S. dollars with a weighted average price of $1.55 and a weighted average remaining life of 1.15 years.
During the quarter ended September 30, 2017, there were 21 warrants exercised resulting in gross proceeds to the Company of $31.

Warrant

Common Shares Issuable Upon Exercise of

Exercise Price

Description

Outstanding Warrants at September 30, 2017

$USD

Expiration Date

Investor warrants

1,312

$1.50 USD

November 22, 2018

Investor warrants

50

$3.00 USD

February 2, 2019

Total

1,362

Stock option plan

The Compensation Committee of the Board of
Directors administers the Company’s stock option plan. The Compensation Committee designates eligible participants to
be included under the plan and approves the number of options to be granted from time to time under the plan. Currently, the maximum
number of option shares issuable is twenty-five percent (25%) of the total number of issued and outstanding shares of common stock. Based
upon the current shares outstanding, a maximum of 3,964 options are authorized for issuance under the plan. For all options
issued under the plan, the exercise price is the fair value of the underlying shares on the date of grant. All options vest
within three years or less and are exercisable for a period of seven years from the date of grant. The stock option plan allows
the issuance of Canadian and U.S. dollar grants. The table below outlines recognized contractor and employee expense for the
three and nine month periods ended September 30, 2017 and 2016.

The following is a summary of option activity
for each of the quarterly periods in fiscal year 2017 for stock options denominated in US dollars:

Number of

Weighted-Average

US Denominated Options

Options (thousands)

Exercise Price $USD

Outstanding December 31, 2016

1,428

1.93

Granted

-

-

Exercised

-

-

Forfeited

-

-

Outstanding at March 31, 2017

1,428

1.93

Granted

300

4.84

Exercised

(50

)

0.64

Forfeited

-

-

Outstanding at June 30, 2017

1,678

2.48

Granted

21

6.72

Exercised

(72

)

1.69

Forfeited

(3

)

2.79

Outstanding at September 30, 2017

1,624

2.57

During the three and nine month periods ended
September 30, 2017, US denominated option exercises provided gross proceeds of $121 and $153, respectively. US denominated option
exercises during the three and nine month periods ended September 30, 2017, resulted in the issuance of 72 and 122 common shares,
respectively. Of the 1,624 options granted and outstanding at September 30, 2017, 1,348 are fully vested and exercisable.

The following is a summary of option activity
for the three and nine months ended September 30, 2017 for stock options denominated in Canadian dollars:

Number of

Weighted-Average

Canadian Denominated Options

Options (thousands)

Exercise Price $CAD

Outstanding December 31, 2016

999

2.38

Exercised

-

-

Forfeited

-

-

Outstanding at March 31, 2017

999

2.38

Exercised

(36

)

2.42

Forfeited

-

-

Outstanding at June 30, 2017

963

2.37

Exercised

(135

)

2.43

Forfeited

(91

)

2.40

Outstanding at September 30, 2017

737

2.36

For the nine months ended September 30, 2017, there was no issuance
activity related to Canadian dollar denominated options. During the three months ended September 30, 2017, there were exercises
of 135 Canadian denominated options which resulted in gross proceeds of CAD$329 ($261 as presented in US dollars). During the nine
months ended September 30, 2017, there were exercises of 171 Canadian denominated options (1 treated as a derivative, 170 as non-derivative).
These exercises resulted in gross proceeds of CAD$416 ($326 as presented in US dollars). During the same three and nine month periods
ended 2016, Canadian denominated option activity consisted of 324 forfeitures. As of September 30, 2017, all outstanding options
denominated in Canadian dollars were fully vested.

Valuation assumptions

The value of options granted were estimated
using the Black-Scholes option pricing model using the following assumptions in the table below: The expected volatility was determined
using historical volatility of our stock based on the contractual life of the award. There were 21 options issued during the three
months ended September 30, 2017, (285 for the same period in 2016). Assumptions for the valuation of the option grants are described
in the table below:

On June 27, 2017, the Company’s shareholders
approved a Shareholder Rights Plan Agreement (the "Rights Plan") for the Company. The Rights Plan is to ensure, to the
extent possible, that all shareholders of the Corporation are treated fairly and equally in connection with any take-over bid or
other acquisition of control of the Corporation. The Rights Plan is designed to require any potential transaction that will result
in a person owning, in the aggregate, 20% or more of the outstanding Common Shares to be structured as a formal take-over bid that
satisfies certain minimum requirements relating primarily to the manner in which the bid must be made, the minimum number of days
the bid must remain open, and the minimum number of shares that must be acquired under the bid.

7.

Fair Value Measurements

The Company adopted the Fair Value Measurements
and Disclosure Topic of the FASB in 2011. This Topic applies to certain assets and liabilities that are being measured and reported
on a fair value basis. The Topic defines fair value, establishes a framework for measuring fair value in accordance with US GAAP,
and expands disclosure about fair value measurements. This Topic enables the reader of the financial statements to assess the inputs
used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used
to determine fair values. The Topic requires that financial assets and liabilities carried at fair value be classified and disclosed
in one of the following three categories:

Level 2: Observable market based inputs or
unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs that are not corroborated
by market data.

Fair Value Measurement at September 30, 2017

Assets/Liabilities Measured at Fair Value on a Recurring Basis

Quoted Price in Active Markets for Identical Instruments

Significant Other Observable Inputs

Significant Unobservable Inputs

Level 1

Level 2

Level 3

Total

Assets

Cash and cash equivalents

$

440

(1)

$

9,248

$

-

$

9,688

Liabilities

Derivative liabilities

-

-

373

373

(1)

The Company held $440 in cash of which $282 (as presented in US dollars) was in Canadian funds.

The Company's financial instruments include
cash and cash equivalents and derivatives. The derivative liabilities include options issued to contractors in a currency other
than the functional currency of the Company.

8.

Commitments and Contingencies

Oregon Health & Science University Agreement

On February 20, 2013, Fennec entered into a
new exclusive license agreement with Oregon Health & Science University (“OHSU”) for exclusive worldwide license
rights to intellectual property directed to STS and its use for chemoprotection, including the prevention of ototoxicity induced
by platinum chemotherapy, in humans (the "New OHSU Agreement").

The term of the New OHSU Agreement expires
on the date of the last to expire claim(s) covered in the patents licensed to the Company, unless earlier terminated as provided
in the agreement. STS is currently protected by methods of use patents that the Company exclusively licensed from OHSU that expire
in Europe, Canada and Australia in 2021 and are currently pending in the United States and Japan. The New OHSU Agreement is terminable
by either Fennec or OHSU in the event of a material breach of the agreement by either party after 45 days prior written notice.
Fennec has the right to terminate the New OHSU Agreement at any time upon 60 days prior written notice and payment of all fees
due to OHSU under the New OHSU Agreement.

On May 18, 2015, Fennec negotiated an amendment
("Amendment 1") to the exclusive license agreement with OHSU. Amendment 1 expands the exclusive license agreement signed
with OHSU on February 20, 2013 or New OHSU Agreement to include the use of N-acetylcysteine as a standalone therapy and/or in combination
with Sodium Thiosulfate ("STS") for the prevention of ototoxicity induced by chemotherapeutic agents to treat cancers.
Further, Amendment 1 adjusts select milestone payments entered in the OHSU Agreement including but not limited to the royalty rate
on net sales for licensed products, royalty rate from sublicensing of the licensed technology and the fee payable upon the regulatory
approval of a licensed product. The term of Amendment 1 under the OHSU Agreement expires on the date of the last to expire claim(s)
covered in the patents licensed to Fennec or 8 years, whichever is later. In the event a licensed product obtains regulatory approval
and is covered by the Orphan Drug Designation, the parties will in good faith amend the term of the agreement.

In the event of his termination with us other
than for cause, the Company will pay its Chief Executive Officer, Rostislav Raykov, a one-time severance compensation payment equal
to 12 months of salary (currently $275). Further, the Company will pay Chief Financial Officer, Robert Andrade, a one-time severance
compensation equal to six-months salary (currently $100).

Leases

The Company has an operating lease in Research
Triangle Park, North Carolina. This operating lease is terminable with 30 days’ notice and has no penalties or contingent
payments due. The Company had rent expense of $1 during the quarter ended September 30, 2017 and $3 for the nine months ended September
30, 2017.

9.

Subsequent events

Registration of Certain Common Shares and
Warrants (S-3 & S-8)

On October 24, 2017, the Company filed a S-3
registration of common shares, pursuant to which the Company may offer from time to time, shares of our common stock having an
aggregate offering price of up to $90.0 million. Under the Sales Agreement, the Company may sell shares by any method permitted
by law and deemed to be an “at-the-market” offering as defined in Rule 415 promulgated under the Securities Act, as
amended, including sales made directly on the NASDAQ, on any other existing trading market for our common stock or to or through
a market maker. The S-3 registration became effective on November 3, 2016. As of the date of this filing, there have been no such
sales.

On October 24, 2017, the Company filed a S-8
registering its 2,631 outstanding options. The S-8 registration became effective upon filing.

13

Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations

CAUTIONARY STATEMENT

The discussion below contains forward-looking
statements regarding our financial condition and our results of operations that are based upon our latest unaudited interim condensed
consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles within
the United States, or US GAAP, and applicable U.S. Securities and Exchange Commission, or SEC, regulations for financial information. The
preparation of these unaudited interim condensed consolidated financial statements requires our management to make estimates and
judgments that affect the reported amounts of assets, liabilities, income and expenses, and related disclosure of contingent assets
and liabilities. We evaluate our estimates on an ongoing basis. Our estimates are based on historical experience and
on various other assumptions that we believe to be reasonable. All amounts are presents in the U.S. dollars and in thousands except
per share amounts.

Overview

Lead Product Candidate

The following is our
only lead product candidate in the clinical stage of development:

·

PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) – a water soluble
thiol compound that acts as a chemical reducing agent, recently completed patient enrollment of two Phase III clinical trials for
the prevention of cisplatin induced hearing loss, or ototoxicity in children.

We continue to focus the Company’s resources
on the development of PEDMARKTM.

We have licensed from Oregon Health & Science
University (“OHSU”) intellectual property rights for the use of PEDMARKTM as a chemoprotectant, and are
developing PEDMARKTM as a protectant against the hearing loss often caused by platinum-based anti-cancer agents in children.
Preclinical and clinical studies conducted by OHSU and others have indicated that PEDMARKTM can effectively reduce the
incidence of hearing loss caused by platinum-based anti-cancer agents. We have received Orphan Drug Designation in the United States
for the use of PEDMARKTM in the prevention of platinum-induced ototoxicity in pediatric patients.

Hearing loss among children receiving platinum-based
chemotherapy is frequent, permanent and often severely disabling. The incidence of hearing loss in these children depends upon
the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established
preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants
have been shown to provide some benefit. In addition, adults undergoing chemotherapy for several common malignancies, including
ovarian cancer, testicular cancer, and particularly head and neck cancer and brain cancer, often receive intensive platinum-based
therapy and may experience severe, irreversible hearing loss, particularly in the high frequencies.

Investigators at OHSU have conducted Phase
I and Phase II studies which have shown that STS reduces the hearing loss associated with platinum-based chemotherapy. In one study
at OHSU, the need for hearing aids to correct high frequency hearing loss was reduced from about 50% to less than 5%.

STS has been studied by cooperative groups
in two Phase III clinical studies of survival and reduction of ototoxicity, the Clinical Oncology Group (“COG”) Protocol
ACCL0431 and the International Society of Pediatric Oncology (“SIOPEL 6”). The COG ACCL0431 protocol enrolled one of
five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly
diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma
patients with localized tumors.

In 2018, Fennec plans to pursue regulatory
approval for PEDMARKTM based on the data from SIOPEL 6 study along with the proof of principle data from COG ACCL0431.
STS has received Orphan Drug Designation in the US in this setting and plans to pursue European Market Exclusivity for Pediatric
Use upon approval.

SIOPEL 6

In October 2007, we announced that our collaborative
partner, the International Childhood Liver Tumour Strategy Group, known as SIOPEL, a multi-disciplinary group of specialists under
the umbrella of the International Society of Pediatric Oncology, had launched a randomized Phase III clinical trial ("SIOPEL
6") to investigate whether STS reduces hearing loss in standard risk hepatoblastoma (liver) cancer patients receiving cisplatin
as a monotherapy.

The study was initiated in October 2007 initially
in the United Kingdom and completed enrollment at the end of 2014, 52 sites from 11 countries enrolled 109 evaluable patients.
Under the terms of our agreement, SIOPEL will conduct and fund all clinical activities and Fennec will provide drug, drug distribution
and pharmacovigilance, or safety monitoring, for the study was completed in December 2014 and the results of the trial were released
in October 2017 at SIOP 2017.

The primary objectives of SIOPEL 6 are:

·

To assess the efficacy of STS to reduce the hearing impairment caused by cisplatin

·

To carefully monitor any potential impact of STS on response to cisplatin and survival

14

SIOPEL 6 - Results - October 2017

Background / Objectives:

Background: Bilateral high-frequency hearing
loss is a serious permanent side-effect of cisplatin therapy; particularly debilitating when occurring in young children. STS has
been shown to reduce cisplatin induced hearing loss. SIOPEL 6 is a phase III randomised trial to assess the efficacy of STS in
reducing ototoxicity in young children treated with cisplatin (Cis) for SR-HB.

Design / Methods:

Methods: Newly diagnosed patients with
SR-HB, defined as tumour limited to PRETEXT I, II or III, no portal or hepatic vein involvement, no intra-abdominal extrahepatic
disease, AFP >100ng/ml and no metastases, were randomised to Cis or Cis+STS for 4 preoperative and 2 postoperative courses.
Cisplatin 80mg/m2 was administered over 6 hours, STS 20g/m2 was administered intravenously over 15 minutes exactly 6 hours after
stopping cisplatin. Tumour response was assessed after 2 and 4 preoperative cycles with serum AFP and liver imaging. In case
of progressive disease (PD), STS was to be stopped and doxorubicin 60mg/m2 combined to cisplatin. The primary endpoint is
centrally reviewed absolute hearing threshold, at the age of ≥3.5 years by pure tone audiometry.

Results:

Results: One hundred and nine randomised
patients (52 Cis and 57 Cis+STS) are evaluable. The combination of Cis+STS was generally well tolerated. With a follow up of 52months,
3yr EFS is Cis 78.8% and Cis+STS 82.1% 3yr OS is Cis 92.3% and Cis+STS 98.2%. Treatment failure defined as PD at 4 cycles was equivalent
in both arms. Among the first 99 evaluable patients, hearing loss occurred in 30/45=67.0% under Cis and in 20/54=37.0% under Cis+STS,
corresponding to a relative risk of 0.56(P=0.0033).

Conclusions:

This randomised phase III trial in SR-HB
of cisplatin versus cisplatin plus sodium thiosulfate shows that the addition of sodium thiosulfate significantly reduces the incidence
of cisplatin-induced hearing loss without any evidence of tumour protection.

COG ACCL0431

In March 2008, we announced the activation of a Phase III trial
with STS to prevent hearing loss in children receiving cisplatin-based chemotherapy in collaboration with the Children’s
Oncology Group (“COG ACCL0431”). The goal of this Phase III study is to evaluate in a multi-centered, randomized trial
whether STS is an effective and safe means of preventing hearing loss in children receiving cisplatin-based chemotherapy for newly
diagnosed germ cell, liver (hepatoblastoma), brain (medulloblastoma), nerve tissue (neuroblastoma) or bone (osteosarcoma) cancers.
Eligible children, one to eighteen years of age, who are to receive cisplatin according to their disease-specific regimen and,
upon enrollment in this study, will be randomized to receive STS or not. Efficacy of STS will be determined through comparison
of hearing sensitivity at follow-up relative to baseline measurements using standard audiometric techniques. The Children’s
Oncology Group is responsible for funding the clinical activities for the study and we are responsible for providing the drug,
drug distribution and pharmacovigilance, or safety monitoring, for the study. The trial completed enrollment of 131 pediatric patients
in the first quarter of 2012. The final results of COG ACCL0431 were published in Lancet Oncology in December 2016.

15

COG ACCL0431 - Results

COG Study ACCL0431, “A Randomized Phase
III Study of Sodium Thiosulfate for the Prevention of Cisplatin-Induced Ototoxicity in Children,” finished enrollment of
131 of which 126 were eligible patients in Q1 2012. The patients had been previously diagnosed with childhood cancers.

The primary endpoint was to evaluate the efficacy
of STS for prevention of hearing loss in children receiving cisplatin chemotherapy (hypothesis: 50% relative reduction in hearing
loss).

Secondary endpoints included:

·

Compare change in mean hearing thresholds

·

Compare incidence of other Grade 3/4 toxicities (renal and hematological)

Subjects were randomized either to no treatment
(control) or treatment with STS 16 grams/m2 IV over 15 minutes 6 hours after each cisplatin dose. Hearing was measured using standard
audiometry for age and data were reviewed centrally using American Speech-Language-Hearing Association criteria.

The proportion of subjects with hearing loss
assessed at 4 weeks post the final cisplatin dose (primary endpoint)..

In a predefined subgroup of patients less than 5 years old with 29 eligible subjects: STS vs. Control
was 21.4% (3/14) vs. 73.3% (11/15), respectively (p=0.005)

Conclusions:

·

STS protects against cisplatin-induced hearing loss in children across a heterogeneous range of tumor types with even stronger
efficacy in the protocol predefined subgroup of patients under five years old and is not associated with serious adverse events
attributed to its use.

Capital Funding

We have not received and do not expect to have
significant revenues from our product candidate until we are either able to sell our product candidate after obtaining applicable
regulatory approvals or we establish collaborations that provide us with up-front payments, licensing fees, milestone payments,
royalties or other revenue.

We generated a net loss of approximately $4.8
million for the nine months ended September 30, 2017 and a net loss of $1.6 million for the nine months ended September 30, 2016
(inclusive of a non-cash loss on derivatives of $0.34 million and $0.05 million non-cash gain on derivatives for the nine months
ended September 30, 2017 and 2016, respectively). As of September 30, 2017, our accumulated deficit was approximately $119.1 million
($114.3 million at December 31, 2016).

We believe that our cash and cash equivalents
as of September 30, 2017, which totaled $9.7 million, will be sufficient to meet our cash requirements through and beyond current
fiscal year. Because of our limited financial resources, we have postponed or terminated many of our previously planned or ongoing
clinical development programs. We continue to pursue various strategic alternatives, including collaborations with other pharmaceutical
and biotechnology companies. As a result, there is uncertainty of our ability to continue as a going concern. Our projections
of our capital requirements are subject to substantial uncertainty. More capital than we anticipated may be required
thereafter. To finance our continuing operations, we will need to raise substantial additional funds through either the sale
of additional equity, the issuance of debt, the establishment of collaborations that provide us with funding, the out-license or
sale of certain aspects of our intellectual property portfolio or from other sources. Given current economic conditions,
we might not be able to raise the necessary capital or such funding may not be available on financially acceptable terms if at
all. If we cannot obtain adequate funding in the future, we might be required to further delay, scale back or eliminate certain
research and development studies, consider business combinations or even shut down our operations.

Our operating expenses will depend on many
factors, including the progress of our drug development efforts and the implementation of further cost reduction measures. Our
research and development expenses, which include expenses associated with our clinical trials, drug manufacturing to support clinical
programs, salaries for research and development personnel, stock-based compensation, consulting fees, sponsored research costs,
toxicology studies, license fees, milestone payments, and other fees and costs related to the development of our product candidate,
will depend on the availability of financial resources, the results of our clinical trials and any directives from regulatory agencies,
which are difficult to predict. Our general and administration expenses include expenses associated with the compensation of employees,
stock-based compensation, professional fees, consulting fees, insurance and other administrative matters associated in support
of our drug development programs.

16

Use of Proceeds

On September 18, 2017,
the Company’s registration statement on Form S-1 (File No. 333-219884) was declared effective, pursuant to which the Company
registered the sale of 11,943,214 shares of common shares, including 1,383,331 shares issuable upon the exercise of outstanding
warrants, all of which were to be sold by selling stockholders. All of the shares are to be sold by selling stockholders at prevailing
market prices or privately negotiated prices. We did not receive any proceeds from the sale of securities by the selling stockholders.
However, upon any exercise of the warrants we will receive the exercise price of the warrants.

Results of Operations

Three months ended September 30, 2017 versus
three months ended September 30, 2016:

Three Months

Three Months

Ended

Ended

In thousands of U.S. Dollars

September 30, 2017

%

September 30, 2016

%

Change

Revenue

$

-

$

-

$

-

Operating expenses:

Research and development

492

23

%

112

20

%

380

General and administration

1,694

77

%

452

80

%

1,242

Total operating expenses

2,186

100

%

564

100

%

1,622

Loss from operations

(2,186

)

(564

)

(1,622

)

Unrealized (loss)/gain on derivatives

(183

)

19

(202

)

Sale of Eniluracil

-

40

(40

)

Other gain

1

-

1

Interest income and other

16

3

13

Net loss and total comprehensive loss

$

(2,352

)

$

(502

)

$

(1,850

)

Research and development expenses increased
for the three months ended September 30, 2017 over the same period in 2016 as the Company increased expenditures on PEDMARKTM
development. This increase relates primarily to drug manufacturing activities and preparations for registration activities.

General and administrative expenses increased
over same period in 2016. The increase was primarily a result of the increase in non-cash equity compensation expenses for employees
compared with the same period in 2016.

The Company recorded
an unrealized loss on derivatives of $183 in the three months ended September 30, 2017 compared to a gain of $19 for the same three
months ended in 2016. In the past, the derivative warrant liability was significant and had the ability to produce large swings
in non-cash gains and losses in any given period, depending upon market conditions. The remaining derivative liability on the balance
sheet is associated with the Company’s Canadian denominated options. Although, there are very few derivative options remaining
on the books of the Company, the recent surge in share price has had a noticeable effect on the value of these derivatives. These
option derivatives have been recorded at their fair value as a liability at issuance and will continue to be re-measured at fair
value as a liability at each subsequent balance sheet date. Any change in value between reporting periods will be recorded as an
unrealized gain/(loss). These options will continue to be reported as a liability until such time as they are exercised or expire.
The fair value of these options is estimated using the Black-Scholes option-pricing model.

17

Our results of operations
for the nine months ended September 30, 2017 versus nine months ended September 30, 2016 were as follows:

Nine Months

Nine Months

Ended

Ended

In thousands of U.S. Dollars

September 30, 2017

%

September 30, 2016

%

Change

Revenue

$

-

$

-

$

-

Operating expenses:

Research and development

1,050

24

%

298

17

%

752

General and administration

3,386

76

%

1,427

83

%

1,959

Total operating expenses

4,436

100

%

1,725

100

%

2,711

Loss from operations

(4,436

)

(1,725

)

(2,711

)

Unrealized (loss)/gain on derivatives

(340

)

45

(385

)

Sale of Eniluracil

-

40

(40

)

Other loss

(4

)

(12

)

8

Interest income and other

24

6

18

Net loss and total comprehensive loss

$

(4,756

)

$

(1,646

)

$

(3,070

)

Total research and
development expenses were up by $752 for the nine months ended September 30, 2017 over the same period in 2016. This increase relates
primarily to drug manufacturing activities and preparations for registration batches. General and administrative costs increased
over the prior year in the same period primarily due to the issuance of equity based compensation.

Changes in the valuation
of derivative liabilities are primarily driven by volatility in the Company’s share price. Since February of 2017, the Company’s
share price has increased. This has caused a significant fluctuation in the value of the derivative liabilities on our books. The
result has been a 385 increase in non-cash loss on derivative valuation for the nine months ended September 30, 2017 over the same
period in 2016.

Quarterly Information

The following table presents selected condensed
financial data for quarters through September 30, 2017, as prepared under US GAAP (U.S. dollars in thousands, except per share
information):

Cash and cash equivalents were $9,688 at September
30, 2017 and $3,926 at December 31, 2016. The increase in cash and cash equivalents between September 30, 2017 and December 31,
2016 is primarily due to cash received from the exercise of various warrants and options and the completion of an equity financing
in May 2017. These increases in cash were offset by cash spent on research and development and general and administrative activities.
The Company received $7,571 net of issuance costs from the equity financing and $512 from the exercise of options and warrants.
The Company issued a total of 2,214 shares as a result of these activities.

The following table illustrates a summary of
cash flow data for the three and nine month periods of September 30, 2017 and 2016:

Dollar and shares in thousands Selected cash flow data:

Three Months Ended September 30,

Nine months Ended September 30,

2017

2016

2017

2016

Net cash used in operating activities

$

(958

)

$

(544

)

$

(2,321

)

$

(1,513

)

Net cash provided by investing activities

-

-

-

-

Net cash provided by financing activities

414

-

8,083

5,108

Increase in cash and cash equivalents

$

(544

)

$

(544

)

$

5,762

$

3,595

Net cash used in operating activities for the
three months ended September 30, 2017 was $958, as compared to $544 during the same period in 2016. This increase in cash outlays
relates the preparation of registration including manufacturing of registration batches. Net cash provided by financing activities
for the three months ended September 30, 2017 was $414 compared to $0 for the three months ended September 30, 2016. The $414 provided
by financing activities, derived from the exercise of 207 options and 21 warrants. For the same three-month period in 2016, there
was no cash resulting from financing activities. Total decrease in cash and cash equivalents was $544 for the three months ended
September 30, 2017, and for the same period in 2016.

Net cash used in operating activities for the
nine months ended September 30, 2017 was $2,321, as compared to $1,513 during the same period in 2016. This increase is due to
increased cash outlays incurred from research and development in addition to increased general and administrative costs associated
with the Company’s preparation for registration. Net cash provided by financing activities for the nine months ended September
30, 2017 was $8,083 compared to $5,108 for the nine months ended September 30, 2016. The $8,083 includes $7,571 net proceeds from
the receipt of equity financing and $481 and $31 in cash representing the exercise of 293 options and 31 warrants, respectively.
Total increase in cash and cash equivalents was $5,762 for the nine months ended September 30, 2017 which is an increase of $2,167
over the same period in 2016.

We continue to pursue various strategic alternatives
including collaborations with other pharmaceutical and biotechnology companies. Our projections of further capital requirements
are subject to substantial uncertainty. Our working capital requirements may fluctuate in future periods depending upon numerous
factors, including: our ability to obtain additional financial resources; our ability to enter into collaborations that provide
us with up-front payments, milestones or other payments; results of our research and development activities; progress or lack of
progress in our preclinical studies or clinical trials; unfavorable toxicology in our clinical programs, our drug substance requirements
to support clinical programs; change in the focus, direction, or costs of our research and development programs; personnel related
costs; the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our patent claims; competitive
and technological advances; the potential need to develop, acquire or license new technologies and products; our business development
activities; new regulatory requirements implemented by regulatory authorities; the timing and outcome of any regulatory review
process; and commercialization activities, if any.

We had cash and cash equivalents of approximately
$9.7 million as of September 30, 2017.

Outstanding Share Information

The outstanding share data for our company as of September 30, 2017
and December 31, 2016 was as follows (in thousands):

September 30, 2017

December 31, 2016

Change

Common shares

15,857

13,643

2,214

Warrants

1,362

1,383

(21

)

Stock options

2,361

2,427

(66

)

Total

19,580

17,453

2,127

19

Financial Instruments

We invest excess cash and cash equivalents
in high credit quality investments held by financial institutions in accordance with our investment policy designed to protect
the principal investment. At September 30, 2017, we had approximately $9.7 million in cash accounts. We have not experienced any
loss or write down of our money market investments since inception.

Our investment policy is to manage investments
to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment.
Investments may be made in U.S. or Canadian obligations and bank securities, commercial paper of U.S. or Canadian industrial companies,
utilities, financial institutions and consumer loan companies, and securities of foreign banks provided the obligations are guaranteed
or carry ratings appropriate to the policy. Securities must have a minimum Dun & Bradstreet rating of A for bonds or R1 low
for commercial paper. The policy also provides for investment limits on concentrations of securities by issuer and maximum-weighted
average time to maturity of twelve months. This policy applies to all of our financial resources.

The policy risks are primarily the opportunity
cost of the conservative nature of the allowable investments. As our main purpose is research and development, we have chosen to
avoid investments of a trading or speculative nature.

Off-Balance Sheet Arrangements

Since our inception, we have not had any material
off-balance sheet arrangements. In addition, we do not engage in trading activities involving non-exchange traded contracts. As
such, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such
activities.

Research and Development

Our research and development efforts have been
focused on the development of PEDMARKTM since 2013.

We have established relationships with contract
research organizations, universities and other institutions, which we utilize to perform many of the day-to-day activities associated
with our drug development. Where possible, we have sought to include leading scientific investigators and advisors to enhance our
internal capabilities. Research and development issues are reviewed internally by our executive management and supporting scientific
team.

Research and development
expenses for the three months ended September 30, 2017 and 2016 were $492 and $112, respectively and for the nine months then ended,
$1,050 and $298 respectively. The Company has increased its research and development expenses related to PEDMARKTM as
a result of the Company drug manufacturing activities related to the preparation for registration batches.

Our product candidate still requires significant,
time-consuming and costly research and development, testing and regulatory clearances. In developing our product candidate, we
are subject to risks of failure that are inherent in the development of products based on innovative technologies. For example,
it is possible that our product candidate will be ineffective or toxic, or will otherwise fail to receive the necessary regulatory
clearances. There is a risk that our product candidate will be uneconomical to manufacture or market or will not achieve market
acceptance. There is also a risk that third parties may hold proprietary rights that preclude us from marketing our product candidate
or that others will market a superior or equivalent product. As a result of these factors, we are unable to accurately estimate
the nature, timing and future costs necessary to complete the development of this product candidate. In addition, we are unable
to reasonably estimate the period when material net cash inflows could commence from the sale, licensing or commercialization of
such product candidate, if ever.

Critical Accounting Policies and Estimates

The preparation of financial statements in
conformity with US GAAP requires management to make estimates that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses
during the reporting period. These estimates are based on assumptions and judgments that may be affected by commercial, economic
and other factors. Actual results could differ from these estimates.

Our accounting policies are consistent with
those presented in our annual consolidated financial statements included in our Annual Report on Form 10-K for the year ended December
31, 2016.

Item 3. Quantitative and Qualitative
Disclosures about Market Risk

Money Market Investments

We maintain an investment portfolio consisting
of U.S. or Canadian obligations and bank securities and money market investments in compliance with our investment policy. We do
not hold any mortgaged-backed investments in our investment portfolio. Securities must have a minimum Dun & Bradstreet rating
of A for bonds or R1 low for commercial paper. The policy also provides for investment limits on concentrations of securities by
issuer and maximum-weighted average time to maturity of twelve months. This policy applies to all of our financial resources.

20

At September 30, 2017, we had $9.2 million
in money market investments as compared to $3.9 million at December 31, 2016; these investments typically have minimal risk. The
financial markets had been volatile resulting in concerns regarding the recoverability of money market investments, but those conditions
have stabilized. We have not experienced any loss or write down of our money market investments since inception.

Our investment policy is to manage investments
to achieve, in the order of importance, the financial objectives of preservation of principal, liquidity and return on investment. Our
risk associated with fluctuating interest rates on our investments is minimal and not significant to the results of operations. We
currently do not use interest rate derivative instruments to manage exposure to interest rate changes. As the main purpose
of the Company is research and development, we have chosen to avoid investments of a trade or speculative nature.

Foreign Currency Exposure

We are subject to foreign currency risks as
we purchase goods and services which are denominated in Canadian dollars. To date, we have not employed the use of derivative instruments;
however, we do hold Canadian dollars which we use to pay vendors in Canada and other corporate obligations. At September 30,
2017, the Company held approximately 352 thousand Canadian dollars (282 thousand as presented to U.S. dollars). At December 31,
2016, the company held approximately 87 thousand Canadian dollars (66 thousand as presented into U.S. dollars).

Item 4. Controls and Procedures

(a) Evaluation
of Disclosure Controls and Procedures.

In connection with the preparation of this
report, an evaluation was carried out by the Company’s management, with the participation of the Chief Executive Officer
and the Chief Financial Officer, of the effectiveness of the Company’s disclosure controls and procedures (as defined in
Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (“Exchange Act”)) as of September 30, 2017.
Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted
under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in Securities and Exchange
Commission rules and forms and that such information is accumulated and communicated to management, including the Chief Executive
Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. In designing and evaluating
our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and
operated, can provide only reasonable assurance of achieving the desired control objectives. Based on that evaluation, the Company’s
management concluded, as of the end of the period covered by this report, that the Company’s disclosure controls and procedures
were not effective as a result of having identified two material weaknesses in our internal control over financial reporting, as
described in further detail below.

Our management has identified a control deficiency
due to not maintaining an effective control environment, which is the foundation for the discipline and structure necessary for
effective internal control over financial reporting, as evidenced by: (i) a lack of segregation of duties over individuals responsible
for certain key control activities; (ii) an insufficient number of personnel appropriately qualified to perform control monitoring
activities, including the recognition of the risks and complexities of transactions; and (iii) control activities that are not
designed to respond to the risks identified. This control deficiency could result in a misstatement of balance sheet, income and
cash flow statement accounts in our interim or annual financial statements that would not be detected. Accordingly, management
has determined that this control deficiency constitutes a material weakness.

Our management has also identified another
control deficiency that it believes constitutes a material weakness in our control over financial reporting. We did not maintain
sufficient personnel with an appropriate level of technical accounting knowledge, experience, and training in the application of
US GAAP with regards to unusual transactions commensurate with our complexity and our financial accounting and reporting requirements.
This control deficiency could result in a misstatement of the financial statements including disclosure that would not be prevented
or detected on a timely basis.

We believe the control deficiencies described
herein, individually and when aggregated, represent material weaknesses in our internal control over financial reporting at September
30, 2017 since such deficiencies result in a reasonable possibility that a material misstatement in our annual or interim consolidated
financial statements may not be prevented or detected on a timely basis by our internal controls.

These material weaknesses did not result in
any material misstatements to the financial statements. However, these material weaknesses could result in misstatement of the
aforementioned account balances or disclosures that would result in material misstatements to the annual or interim consolidated
financial statements that would not be prevented or detected.

To finance our continuing operations, we will
need to raise additional funds beyond those from our most recent private placement in June 2017 and, as disclosed elsewhere in
this report, there remains substantial doubt in our ability to continue as a going concern and the failure to obtain such funds
might require us to further delay, scale back or eliminate certain research and development studies, consider business combinations,
or even shut down our operations. If we are able to secure such additional financing, we anticipate hiring additional personnel
with appropriate technical accounting knowledge, experience, and training in the application of U.S. GAAP to supplement our current
accounting staff.

21

(b) Changes
in Internal Control over Financial Reporting

There was no change in our internal control
over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) identified in connection with the
evaluation of our internal control over financial reporting that occurred during the fiscal quarter ended September 30, 2017 that
has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II: OTHER INFORMATION

Item 1. Legal Proceedings.

None

Item 1A. Risk Factors.

Our Annual Report on Form 10-K for the fiscal
year ended December 31, 2016, filed with the SEC on March 29, 2017 (the “Annual Report”), includes a detailed discussion
of our risk factors under the heading “PART I, Item 1A – Risk Factors.” You should carefully consider the risk
factors discussed in our Annual Report, as well as other information in this quarterly report. Any of these risks could cause our
business, financial condition, results of operations and future growth prospects to suffer. We are not aware of any material changes
from the risk factors previously disclosed.

Item 2. Recent Sales of Unregistered Securities.

The following table details grants of stock
options to various contractors, officers and directors of the Company for the period ended September 30, 2017:

Date of Option Grant

Number of Options Granted

Strike Price $USD

August 17, 2017

21,150

$

6.72

The options were issued in a private placement
exempt under Section 4(2) of the Securities Act of 1933, as amended (the "Securities Act"). The options were issued in
USD denominated grants and are each exercisable for a period of 7 years from the grant date.

Pursuant to requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Fennec Pharmaceuticals Inc.

Date: November 13, 2017

By:

/s/ Rostislav Raykov

Rostislav Raykov

Chief Executive Officer

(principal executive officer)

Date: November 13, 2017

By:

/s/ Robert Andrade

Robert Andrade

Chief Financial Officer

(principal financial and chief accounting officer)

24

Exhibit 31.1

FENNEC PHARMACEUTICALS INC

CERTIFICATION

I, Rostislav Raykov, certify that:

1.

I have reviewed this quarterly report on Form 10-Q for
the period ended September 30, 2017 of Fennec Pharmaceuticals Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;

3.

Based on my knowledge, the unaudited interim condensed consolidated financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its condensed subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during
the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors
(or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.

Date: November 13, 2017

By:

/s/Rostislav Raykov

Rostislav Raykov

Chief Executive Officer

Exhibit 31.2

FENNEC PHARMACEUTICALS INC.

CERTIFICATION

I, Robert Andrade, certify that:

1.

I have reviewed this quarterly report on Form 10-Q for the period ended September 30, 2017 of Fennec Pharmaceuticals Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with
respect to the period covered by this report;

3.

Based on my knowledge, the unaudited interim condensed consolidated financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its condensed subsidiaries, is made known
to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on
such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during
the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors
(or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting
which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial
information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.

Date: November 13, 2017

By:

/s/ Robert Andrade

Robert Andrade

Chief Financial Officer

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. §1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF
2002

In connection with the Quarterly Report of Fennec Pharmaceuticals
Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2017 (the “Report”),
each of the undersigned, Rostislav Raykov, Chief Executive Officer of the Company, and Robert Andrade, Chief Financial Officer
of the Company, hereby certifies pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of 2002, that:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.

Date: November 13, 2017

By:

/s/ Rostislav Raykov

Rostislav Raykov

Chief Executive Officer

Date: November 13, 2017

By:

/s/ Robert Andrade

Robert Andrade

Chief Financial Officer

Exhibit 99.1

FENNEC PROVIDES BUSINESS UPDATE AND REPORTS
THIRD QUARTER 2017 RESULTS

· During
the third quarter, the Company announced positive results from its Phase 3 SIOPEL 6 Study

·Cash
position of approximately $10 million allows financial flexibility to pursue regulatory submissions

Research Triangle Park, NC, November
13, 2017 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC TSX: FRX,), a specialty pharmaceutical company focused on the
development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS))
for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its financial results for the third
quarter ended September 30, 2017.

“The
positive results from SIOPEL 6 announced in October represent a significant step in establishing a new paradigm in pediatric oncology
with the potential to benefit the lives of patients and their families," stated Rosty Raykov, CEO of Fennec. "We remain
focused on the steps necessary to complete the regulatory filings in both the US and Europe for approval."

SIOPEL 6 Study

·

SIOPEL 6 study met its primary endpoint
demonstrating that the addition of STS significantly reduces the incidence of cisplatin-induced hearing loss without any evidence
of tumor protection.

·

Among the 99
evaluable patients in SIOPEL 6, hearing loss occurred in 30/45=67% treated with Cisplatin (Cis) alone and in 20/54=37.0% treated
with Cis+STS, corresponding to a relative risk of 0.56(P=0.0033).

·

Fennec plans
to pursue regulatory approval for PEDMARKTM based on the data from the SIOPEL 6 study along with the proof of principle
data from COG ACCL0431.

·

STS has received
Orphan Drug Designation in the US in this setting and plans to pursue European Market Exclusivity for Pediatric Use upon approval.

Upcoming Investor Events:

·

2017
Jefferies London Healthcare Conference - Rosty Raykov, CEO of Fennec, will provide
an overview of the Company's business on Thursday, November 16 at 4:40 pm GMT at the
2017 Jefferies London Healthcare Conference. The
Fennec presentation will be webcast live and can be accessed by visiting the investors
relations sections of the Company’s website at http://fennecpharma.com/investors/presentations-events/ .
A replay of the presentation will also be available and archived on the site for ninety
days.

Third Quarter Financial Results

The selected financial data presented below
is derived from our unaudited condensed consolidated financial statements which were prepared in accordance with U.S. generally
accepted accounting principles. The complete interim unaudited consolidated financial statements for the period ended September
30, 2017 and management's discussion and analysis of financial condition and results of operations will be available via www.sec.gov
and www.sedar.com. All values are presented in thousands unless otherwise noted.

Interim Unaudited Condensed Statement of
Operations

(U.S. Dollars in thousands except per share
amounts)

Three Months Ended

Nine Months Ended

September 30, 2017

September 30, 2016

September 30, 2017

September 30, 2016

Revenue

$

-

$

-

$

-

$

-

Operating expenses:

Research and development

492

112

1,050

298

General and administrative

1,694

452

3,386

1,427

Loss from operations

(2,186

)

(564

)

(4,436

)

(1,725

)

Other:

Unrealized gain on derivatives

(183

)

19

(340

)

45

Sale of Eniluracil

-

40

-

40

Other loss

1

-

(4

)

(12

)

Interest income and other

16

3

24

6

Total other, net

(166

)

62

(320

)

79

Net loss and total comprehensive loss

$

(2,352

)

$

(502

)

$

(4,756

)

$

(1,646

)

Basic net loss per common share

$

(0.15

)

$

(0.04

)

$

(0.32

)

$

(0.13

)

Diluted net loss per common share

$

(0.15

)

$

(0.04

)

$

(0.32

)

$

(0.13

)

Weighted-average number of common shares outstanding, basic

15,740

13,643

14,533

12,469

Weighted-average number of common shares outstanding,
diluted

15,740

13,643

14,533

12,469

Total research and
development expenses were up by $380 and $752 for the three and nine months ended September 30, 2017, respectively, over the same
period in 2016. This increase relates primarily to drug manufacturing activities and preparations for registration batches. General
and administrative costs increased over the prior year in the same period primarily due to the issuance of equity based compensation
and costs associated with the NASDAQ listing.

Changes in the valuation
of derivative liabilities are primarily driven by volatility in the Company’s share price. Since February of 2017, the Company’s
share price has increased. This has caused a significant fluctuation in the value of the derivative liabilities on our books. The
result has been a $202 and $385 increase in non-cash loss on derivative valuation for the three and nine months ended September
30, 2017, respectively, over the same period in 2016.

Fennec Pharmaceuticals Inc.

Balance Sheets

(U.S. Dollars in thousands)

September 30, 2017

December 31, 2016

Assets

Cash and cash equivalents

$

9,688

$

3,926

Other current assets

200

46

Total Assets

$

9,888

$

3,972

Liabilities and stockholders’ equity

Current liabilities

$

657

$

369

Derivative liabilities

373

33

Total stockholders’ equity

8,858

3,570

Total liabilities and stockholders’ equity

$

9,888

$

3,972

At September 30, 2017, the Company had working
capital balance totaling approximately $9.2 million compared to $3.6 million as of December 31, 2016.

Working Capital

Three Months Ended

Selected Asset and Liability Data:

September 30, 2017

December 31, 2016

(U.S. Dollars in thousands)

Cash and cash equivalents

$

9,688

$

3,926

Other current assets

200

46

Current liabilities excluding derivative liability

(657

)

(369

)

Working capital

$

9,231

$

3,603

Selected Equity:

Common stock

$

83,062

$

74,515

Accumulated deficit

(119,078

)

(114,322

)

Stockholders’ equity

8,858

3,570

Cash and cash equivalents were $9,688 at September
30, 2017 and $3,926 at December 31, 2016. The increase in cash and cash equivalents between September 30, 2017 and December 31,
2016 is primarily due to cash received from the completion of an equity financing in June 2017 and exercise of various warrants
and options. These increases in cash were offset by cash spent on research and development and general and administrative activities.
The Company received $7,571 net of issuance costs from the equity financing and $512 from the exercise of options and warrants.
The Company issued a total of 2,214 shares as a result of these activities.

Dollar and shares in thousands Selected cash flow data:

Three Months Ended September 30,

Six Months Ended September 30,

2017

2016

2017

2016

Net cash used in operating activities

(958

)

(544

)

(2,321

)

(1,513

)

Net cash provided by investing activities

-

-

-

-

Net cash provided by financing activities

414

-

8,083

5,108

Increase in cash and cash equivalents

(544

)

(544

)

5,762

3,595

Net cash used in operating activities for the
three months ended September 30, 2017 was $958, as compared to $544 during the same period in 2016. This increase in cash outlays
relates the preparation of registration including manufacturing of registration batches. Net cash provided by financing activities
for the three months ended September 30, 2017 was $414 compared to $0 for the three months ended September 30, 2016. The $414 provided
by financing activities, derived from the exercise of 207 options and 21 warrants. For the same three-month period in 2016, there
was no cash resulting from financing activities. Total decrease in cash and cash equivalents was $544 for the three months ended
September 30, 2017, and for the same period in 2016.

Net cash used in operating activities for the
nine months ended September 30, 2017 was $2,321, as compared to $1,513 during the same period in 2016. This increase is due to
increased cash outlays incurred from research and development in addition to increased general and administrative costs associated
with the Company’s preparation for registration. Net cash provided by financing activities for the nine months ended September
30, 2017 was $8,083 compared to $5,108 for the nine months ended September 30, 2016. The $8,083 includes $7,571 net proceeds from
the receipt of equity financing and $481 and $31 in cash representing the exercise of 293 options and 31 warrants, respectively.
Total increase in cash and cash equivalents was $5,762 for the nine months ended September 30, 2017 which is an increase of $2,167
over the same period in 2016.

Forward looking statements

Except for historical information described
in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties
inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory and guideline
developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents
and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s
products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets,
revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital requirements
in different countries and municipalities, the proposed sale to Elion may not be completed and other risks detailed from time to
time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the
year ended December 31, 2016. Fennec Pharmaceuticals, Inc. disclaims any obligation to update these forward-looking statements
except as required by law.

For a more detailed discussion of related risk
factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

About PEDMARKTM(Sodium Thiosulfate (STS))

Cisplatin and other platinum compounds are
essential chemotherapeutic components for many pediatric malignancies. Unfortunately, platinum-based therapies cause ototoxicity
in many patients, and are particularly harmful to the survivors of pediatric cancer.

In the U.S. and Europe there is estimated that
over 7,000 children are diagnosed with low-to-intermediate risk cancers that may receive platinum based chemotherapy. Low-to-intermediate
risk cancers that receive platinum agents may have overall survival rates of greater than 80% further emphasizing the quality of
life after treatment. The incidence of hearing loss in these children depends upon the dose and duration of chemotherapy, and many
of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only
expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants
and young children at critical stages of development lack speech language development and literacy, and older children and adolescents
lack social-emotional development and educational achievement.

STS has been studied by cooperative groups
in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL
6. Both studies are closed to recruitment. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with
intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor,
osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

About Fennec Pharmaceuticals

Fennec
Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development of PEDMARKTM
for the prevention of platinum-induced ototoxicity in pediatric patients. STS has received Orphan Drug Designation
in the US in this setting. For more information, please visit www.fennecpharma.com.